News / Press Releases
Noninvasix announced today that its LIVOx™ Central Venous Oxygenation Monitor has received Breakthrough Device Designation from the U.S. Food and Drug Administration
Noninvasix will be the first company to non-invasively monitor sepsis by detecting the key indicator of septic shock as early as possible so it can be treated to reduce complications and save lives. The LIVOx Central Venous Oxygenation Monitor can provide for a more effective diagnosis of this life-threatening condition.
With $20M Cash Infusion, Genomenon Seeks to Curate Entire Human Genome
Following the closing of a $20 million Series B funding round […] Genomenon plans to advance its goal of curating the entire human genome through its artificial intelligence-based Mastermind Genomic Search Engine.
Blackstone Growth (BXG) Announces Majority Investment in Supergoop!
Blackstone (NYSE:BX) today announced that funds managed by Blackstone Growth (BXG) (“Blackstone”) have entered into a definitive agreement for a majority investment in Supergoop!, the first protective skincare brand that puts SPF at the forefront
(MICROTRANSPONDER) - FDA Approves First-of-Its-Kind Stroke Rehabilitation System
The U.S. Food and Drug Administration today approved the MicroTransponder Vivistim Paired VNS System. The Vivistim System was granted Breakthrough Device designation. The FDA reviewed the MicroTransponder Vivistim Paired VNS System under the Premarket Approval (PMA) pathway
LTK(rewardstyle) Announces SoftBank Vision Fund 2 Investment
A $300 million investment by SoftBank Vision Fund 2 will supercharge talent and product development across LTK’s creator, brand and consumer shopping experiences
Recuro Health Receives Investment by DeepWork Capital and GPG Ventures
Proceeds to Accelerate Growth, Marketing and Expanded Capabilities in Digital Health. Recuro Health is proud to announce that the company has received additional investment through its partnerships with DeepWork Capital and GPG Ventures, bringing total raised capital to $22 million